This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-HER2/neu scFv‑Fc to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the HER2/neu as well as the biological activity of IL2. The anti‑erbB2 scFv‑Fc‑IL‑2 fusion protein (HFI) has improved ability to mediate ADCC activity in vitro., IL‑2 was recruited to target cells to block HER2 signaling, inhibit or kill tumor cells, improve the immune capacity, reduce the dose of antibody and IL‑2 synergy. This immunocytokine was designed for treating HER-3/neu over-expressing cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-059 | Recombinant Anti-Human ERBB2 VHH Single Domain Antibody | IHC, FC, CA, FuncS | Llama VHH |
TAB-032CT | Anti-Human HER2/neu Single Domain Antibody, Research Grade Biosimilar | WB | Single domain antibody |
TAB-046CT | Anti-Human HER2/neu Single Domain Antibody (TAB-046CT), Research Grade Biosimilar | ELISA, Inhibition, FC | Single domain antibody |
TAB-047CT | Anti-Human HER2/neu Single Domain Antibody (TAB-047CT), Research Grade Biosimilar | WB | Single domain antibody |
HPAB-0725-YJ-VHH | Camelid Anti-ERBB2 Recombinant Single Domain Antibody (HPAB-0725-YJ-VHH) | ELISA | Camelid VHH |
There are currently no Customer reviews or questions for ACFP-SH153. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.